MENU ▼
Read by QxMD icon Read
search
OPEN IN READ APP
JOURNAL ARTICLE

Cytoprotective agent for peptic ulcer prevention in patients taking dual antiplatelet agents: A randomized, double-blind placebo-controlled trial

Rapat Pittayanon, Panida Piyachaturawat, Rungsun Rerknimitr, Piyapan Prueksapanich, Supakarn Chaitongrat, Vorarit Lertsuwunseri, Suphot Srimahachota, Varocha Mahachai
Journal of Gastroenterology and Hepatology 2019 March 28
30919492

BACKGROUND: Long-term use of dual antiplatelets is increasing, and most patients need primary peptic ulcer prophylaxis. The long-term use of proton pump inhibitors (PPIs) is associated with adverse events. We evaluated the efficacy of rebamipide for peptic ulcer prevention.

METHODS: This RCT was conducted between July 2014 and November 2017. Patients receiving dual antiplatelets for ≥1 year with no history of peptic ulcer bleeding or perforation were recruited and randomly assigned to the rebamipide (300 mg/day) group or the placebo group. Patients who used PPIs were excluded. The primary endpoint was a new mucosal break on EGD at 3 or 12 months after treatment initiation. The secondary endpoints were haematocrit (Hct) changes from the baseline, GI bleeding, and chest pain. Antiplatelet function was assessed.

RESULTS: In total, 95 eligible patients were identified; twelve were excluded, and 83 patients were randomized, with 66 (79.5%) and 59 (71.1%) patients eligible at the 3- and 12-month follow-ups, respectively. The baseline characteristics were equivalent between the groups. During the 12 months of follow-up, 13 patients (43.3%) taking rebamipide and 19 (65.5%) taking the placebo experienced mucosal injury (p=0.07). Two patients (6.7%) taking rebamipide and 8 (27.6%) taking the placebo had peptic ulcers ≥5 mm or <5 mm with pigmented spots (p=0.03). The changes in Hct were not different between the two groups. Neither bleeding ulcers nor chest pain was observed.

CONCLUSION: Rebamipide is safe and may prevent peptic ulcers ≥ 5 mm in diameter or those with pigmented spots in patients receiving dual antiplatelets for one year (NCT02166008).

Comments

You need to log in or sign up for an account to be able to comment.

No comments yet, be the first to post one!

Trending on Read

Available on the App Store

Available on the Play Store
Remove bar
Read by QxMD icon Read
30919492
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"